Kezar Life Sciences (NASDAQ:KZR) traded lower on Tuesday after the company announced its Q4 2024 financial results alongside data from a mid-stage trial for its lead asset zetomipzomib in patients ...

KEZAR LIFE SCIENCES ($KZR) posted quarterly earnings results on Tuesday, March 25th. The company reported earnings of -$2.77 per share, beating estimates of -$2.91 by ...

Also Read: Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study In the ITT population: Without regard to ...

Kezar Life Sciences (KZR) reported topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a selective immunoproteasome inhibitor, in patients with autoimmune hepatitis ...

On Friday, William Blair upgraded Kezar Life Sciences (NASDAQ:KZR) stock from Market Perform to Outperform following a virtual event that provided insights into the company's clinical developments.

On Friday, William Blair upgraded Kezar Life Sciences (NASDAQ:KZR) stock from Market Perform to Outperform following a virtual event that provided insights into the company’s clinical developments.

Thanks to its location along the shores of the beautiful Kezar Lake, vacation-goers began building cottages along the shoreline, increasing the town's small, year-round population threefold during ...

Bill and Elaine Markham have been making maple syrup at the Mill Brook Sugarhouse on New Lenox Road for 46 years. They use reverse osmosis to take out 75 percent of the water and an oil boiler to ...